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Background: Development an effective vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV)
is urgent and limited information is available on vaccination in nonhuman primate (NHP)model. We herein report
of evaluating a recombinant receptor-binding domain (rRBD) protein vaccine in a rhesus macaque model.
Methods:Ninemonkeys were randomly assigned to high-dose, low-dose andmock groups,which were immunized
with different doses of rRBD plus alum adjuvant or adjuvant alone at different time points (0, 8, 25 weeks). Immu-
nological analysis was conducted after each immunisation. Monkeys were challenged with MERS-CoV at 14 days
after the ﬁnal immunisation followed by observation for clinical signs and chest X-rays. Nasal, oropharyngeal and
rectal swabs were also collected for analyses. Monkeys were euthanized 3 days after challenge and multiple speci-
mens from tissues were collected for pathological, virological and immunological tests.
Conclusion: Robust and sustained immunological responses (including neutralisation antibody) were elicited by the
rRBD vaccination. Besides, rRBD vaccination alleviated pneumonia with evidence of reduced tissue impairment and
clinical manifestation in monkeys. Furthermore, the rRBD vaccine decreased viral load of lung, trachea and oropha-
ryngeal swabs of monkeys. These data in NHP paves a way for further development of an effective human vaccine
against MERS-CoV infection.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
TheMiddle East respiratory syndrome coronavirus (MERS-CoV) is the
only lineage C betacoronavirus known to infect humans (Annan et al.,
2013; Anthony et al., 2013; van Boheemen et al., 2012). Similarly to se-
vere acute respiratory syndrome coronavirus (SARS-CoV), MERS-CoV in-
fection can result in acute respiratory distress syndrome and organ
dysfunction, including progressive renal function impairment (Zaki
et al., 2012). According to the World Health Organization, by the end of
12 August 2015, a total of 1401 cases had been laboratory conﬁrmed,he MERS-CoV RBD vaccine in
mal Sciences, Chinese Academy
strict, Beijing, China.
al Virology, Ministry of Health,
tion, China CDC, 155 Changbai
wj28@163.com (W. Tan).
. This is an open access article underwith at least 500 deaths following MERS-CoV infection. Among them,
186 MERS-CoV infection cases, including 36 deaths, had been reported
by the Republic of Korea (http://www.who.int/csr/don/12-august-2015-
mers-saudi-arabia/en/). These recent clustered cases ﬁrstly sprang up
outside the Arabian Peninsula, indicating the potential human-to-
human transmission of MERS-CoV. To date, no speciﬁc antiviral drug
exists for MERS-CoV infection and supportive treatment is the mainstay
of management (Zumla et al., 2015). Ribavirin and interferon alfa-2b
exhibited potential in a rhesus macaque model (Falzarano et al., 2013a,
b), but in a retrospective cohort study, ribavirin and interferon alfa-2a
therapy was associated with signiﬁcantly improved survival at 14 days,
but not at 28 days in patients with severe MERS-CoV infection (Omrani
et al., 2014). Besides, speciﬁc peptide fusion inhibitors of MERS-CoV (Lu
et al., 2014), convalescent sera from recovered patient and humanmono-
clonal neutralising antibodies (Jiang et al., 2014; Tang et al., 2014; Ying
et al., 2014) provided a novel approach to MERS-CoV treatment. Howev-
er, more data are needed from animal studies and carefully done clinical
studies (Zumla et al., 2015). Therefore, developing a prophylactic vaccine
against MERS-CoV infection remains a priority (Papaneri et al., 2015).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ing domain (rRBD)-based subunit vaccine is a promising candidate vac-
cine against the SARS-CoV infection. As rRBD of SARS-CoV Spike protein
induced strong neutralisation antibody and long-term protective im-
munity in rabbits and mice and completely protected immunized
mice from SARS-CoV infection (Zhu et al., 2013). Furthermore, high ti-
tres of neutralisation antibodies in non-human primates (NHP)were in-
duced by vaccination with the rRBD of SARS-CoV (Wang et al., 2012).
Experience using rRBD-based subunit vaccines against SARS could in-
form the design of a rRBD-based MERS vaccine. Several human
neutralising antibodies targeting the RBD of the MERS-CoV spike pro-
tein, have been identiﬁed from the naïve-antibody library (Tang et al.,
2014; Ying et al., 2014), suggesting that RBD contains epitopes that
can induce nAbs and therefore may represent a target antigen against
MERS-CoV. Our group and others have conﬁrmed rRBD protein
induced strong neutralising antibody responses against MERS-CoV
infection in mice and rabbits (Du et al., 2013; Lan et al., 2014; Ma
et al., 2014;Mou et al., 2013; Zhang et al., 2015). Although the rRBD sub-
unit vaccine is a highly potent neutraliser of antibodies and T-cell im-
mune responses, no formulation has been tested on a higher animal
model with MERS-CoV challenge to verify its prophylactic efﬁcacy
(Gretebeck and Subbarao, 2015). Recently, MERS-CoV infection and
disease animal models have been developed (Agrawal et al., 2015; de
Wit et al., 2013a,b; Falzarano et al., 2014; Munster et al., 2013; Pascal
et al., 2015; Yao et al., 2013; Zhao et al., 2014), including a rhesus ma-
caque model of naturally permissive MERS-CoV disease (de Wit et al.,
2013a,b; Munster et al., 2013; Yao et al., 2013). We herein evaluate a
rRBD subunit vaccine in a rhesus macaque model, to identify a prophy-
lactic approach that could be used in humans to prevent MERS-CoV
infection.
2. Methods
2.1. Ethics Statement
Animal studies were conducted in strict accordance with the Guide
for the Care and Use of Laboratory Animals of the People's Republic of
China. The study protocol was approved by the Committee on the Ethics
of Animal Experiments of the Chinese Centre for Disease Control and
Prevention. The approved registration number is 20140609015. To
comply with 3R (reduction, replacement, reﬁnement) animal experi-
ment principles, a total of 9 rhesus macaques were used.
During experiments, all procedures were performed under ethyl
ether anaesthesia, and every effort wasmade tominimise suffering. Fol-
lowing inoculation with MERS-CoV, all experiments were conducted
within an animal biosafety level 3 (ABSL-3) facilities.
2.2. Virus and Cell Culture
MERS-CoV strain (hCoV-EMC/2012) was kindly provided by
Professor Fouchier (Erasmus Medical Centre, Netherlands). MERS-CoV
seed stocks were propagated in Vero cells (ATCC Number: CCL-81)
withoutmycoplasma contaminationmaintained in Dulbecco'sModiﬁed
Eagle Medium (DMEM, Invitrogen) supplemented with 10% foetal
bovine serum (FBS), 100 international units (IU)/mL penicillin, and
100 μg/mL streptomycin, cultured at 37 °C in 5% CO2. Seed stocks were
diluted to the desired titre and used to determine the MERS-CoV 50%
tissue culture infection dose (TCID50), and for neutralising antibody
and virus inoculation assays.
2.3. Vaccine Formulation
MERS-CoV rRBD protein, containing a 240-amino-acid fragment
spanning residues 367–606, was prepared using a baculovirus expres-
sion vector system and puriﬁed through a HisTrap HP and Superdex
200 column (GE Healthcare, Bucks, UK) as described previously (Lanet al., 2014; Lu et al., 2013). The rRBDproteinwas admixedwith alumin-
ium hydroxide (alum) adjuvant 1 day before immunisation.
2.4. Animal Immunisation and MERS-CoV Challenge
Nine monkeys were randomly assigned to high-dose (H), low-dose
(L), and mock (M) groups (Table 1). High-dose animals were primed
with 200 μg rRBD and boosted with 100-μg rRBD admixed with 1 mg
of alum adjuvant. The three low-dose animals were primed with 50 μg
rRBD and boosted with 25 μg rRBD admixed with 1 mg of alum adju-
vant; control animals were immunised with PBS with 1 mg of alum
adjuvant. Animals received their second immunisation 8 weeks subse-
quent to their ﬁrst. To assess long-term immunological responses, the
interval between the second and third immunisations was 17 weeks.
Each vaccine formulation was administered intramuscularly (i.m.).
Two weeks after each immunisation, animals were bled periodically to
obtain serum and peripheral blood mononuclear cells (PBMCs) for im-
munological analysis.
One week after the ﬁnal immunisation, animals were transferred to
an ABSL-3 laboratory. Following an adaptive phase of 1 week, nine
immunisedmonkeyswere anaesthetised and inoculated intratracheally
with MERS-CoV of the hCoV-EMC strain at a dosage of 6.5 × 107 TCID50,
diluted in 1-mL DMEM. After the challenge with MERS-CoV, monkeys
were observed twice daily, with detailed recording of clinical signs
and symptoms,morbidity andmortality, including the nature, onset, se-
verity and duration of all gross or visible changes. Chest X-rays were
performed 1 day pre- and 1 and 3 days post-inoculation (dpi) with
MERS-CoV. Nasal, oropharyngeal and rectal swabs were collected at
the same time points. Three days after challenge withMERS-CoV, mon-
keys were euthanized and tissue specimens, including lungs, trachea,
spleen and kidney, were collected for various pathological, virological,
and immunological tests. The schematic of the vaccination schedule
and biological specimen collection timeline are displayed in Fig. 1.
2.5. IgG Antibody Analyses Using Enzyme-linked Immunosorbent Assay
(ELISA)
Animals were bled periodically throughout the study (Fig. 1) to de-
rive serum for antibody detection. Endpoint anti-RBD IgG antibody ti-
tres were determined by ELISA as described previously (Lan et al.,
2014).
2.6. Pseudovirus Neutralisation Assay
A MERS-CoV pseudovirus system was conducted within biosafety
level-2 facilities as reported previously (Lan et al., 2014). Relative
light units were determined immediately using a Gaomax lumino-
meter (Promega). All experiments were performed in triplicate. The
pseudovirus inhibition (PI) rate was calculated as follows:
ðRelative luciferase units of mock sera – Relative luciferase units of
immune serum for a given dilutionÞ = Relative luciferase units of
mock sera:
2.7. Neutralising Antibody to hCoV-EMC
The virus neutralisation assay was conducted on Vero Cells. Brieﬂy,
sera were diluted twofold and mixed with 50 μL of 2 × 103 TCID50/mL
virus, incubated at 37 °C for 1 h in quadruplicate. Thereafter, 100-μL
virus-serum mixture was added to Vero cells previously seeded at
1.5 × 104/well. Inoculated plates were incubated in a CO2 incubator at
37 °C for 3 days, following which the cytopathic effects (CPEs) of the
virus were observed microscopically at 40× magniﬁcation. All tests
were repeated twice independently.
Table 1
Rhesus macaque vaccination group.
Group Code Gender Age Vaccine Immunisation (i.m.) Challenge (i.t.) with
MERS-CoV (TCID50)1st 2nd 3rd
M (mock) 6# M 6 PBS 100 μL 100 μL 100 μL 6.5 × 107
4# M 7
12# F 5
H (high-dose) B# M 6 rRBD 200 μg 100 μg 100 μg 6.5 × 107
F# F 5
G# F 7
L (low-dose) A# M 5 rRBD 50 μg 25 μg 25 μg 6.5 × 107
D# M 7
H# F 7
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To evaluate the antigen-speciﬁc T-cell response induced by rRBD
protein in immunised monkeys, an IFN-γ ELISpot assay was performed
as described previously (Wen et al., 2013). After PBMCs were isolated
fromEDTA-treated blood, IFN-γ ELISpot assaywas carried out according
to the manufacturer's instructions. Brieﬂy, 2.5 × 105 cells per well were
stimulated with pools of 15-mer peptides overlapping by 11 amino
acids spanning the RBD protein of MERS-CoV at a ﬁnal concentration
of 4 μg/mL into a PVDF membrane-bottomed plate pre-coated with
anti-monkey IFN-γ capture antibody. A set of negative control wells
comprising media only were included on each plate. After stimulation
for 20–24 h, IFN-γ-spot-forming cells were detected by staining
membranes with the detection antibody (7-B6-1-biotin) followed
by streptavidin-horseradish peroxidase and development with TMB
(3, 3′, 5, 5′-tetramethylbenzidine) substrate solution. Results are pre-
sented as spot-forming cells per 106 PBMCs. Values were reported as
themean of the test wells minus themean of all negative-control wells.
2.9. RNA Extraction and Quantiﬁcation Real-time Polymerase Chain Reac-
tion (qRT-PCR)
Total RNA was isolated from individual samples using the RNeasy
Mini Kit (Qiagen) and reverse transcription reactions were performed
using the Superscript III First Strand Synthesis Kit (Invitrogen), as de-
scribed previously (Yao et al., 2013), to derive complementary DNA
(cDNA). All cDNA samples were stored at−20 °C until use in the qRT-
PCR, targeted to upE as described previously (Corman et al., 2012).
2.10. Viral Isolation From Tissue and Swab Samples
Even though the qRT-PCR is considered as a highly sensitive assay
for detection the viral nucleic acid, an assay of viral isolation is absolute
necessity to detect the real viral replication. To this end, all tissues were
homogenised to a ﬁnal 10% suspension in DMEM and clariﬁed by low-Fig. 1. Schematic diagram of the rRBD vaccination andMERS-CoV challenge schedule. Monkeys
oculated intratracheally with hCoV-EMC at a dosage of 6.5 × 107 TCID50 (red arrow).Monkeys w
Additionally, nasal, oral and rectal swabswere collected at−1 day, 1 day and 3 days. Chest X-ra
trachea, spleen and kidney specimens of challenged monkeys were acquired at 3 dpi for detecspeed centrifugation at 4500 g for 30 min at 4 °C. Swab samples were
immersed in 1-mL DMEM, vortexed, and clariﬁed by low-speed centri-
fugation at 5000 g for 10 min at 4 °C. Virus titres were determined in
Vero cell monolayers grown in 96-well plates as described previously
(Yao et al., 2013). In brief, 1.5 × 104/well of Vero cells were seeded in
a 96-well plate and incubated overnight at 37 °C in a CO2 incubator.
One-hundred microliters of 10-fold serially diluted suspension was
then added to each well in quadruplicate. The virus was allowed to ad-
sorb to the cells at 37 °C for 1 h. After adsorption, viral inocula were re-
moved, and 100 μL of DMEM (2% FBS) was added to each well. Plates
were incubated in a CO2 incubator at 37 °C for 3 days, following which
CPEs were observed microscopically at 40× magniﬁcation. The virus ti-
tres expressed as the TCID50 of each specimen were calculated by the
Reed–Muench method.2.11. Histopathology and Immunohistochemistry
Necropsy was performed on all animals according to the standard
protocol. Lung, trachea, spleen andkidney tissue sampleswere collected
for histopathological and immunohistochemical examination. Proce-
dures were performed using ﬁxed 10% neutral buffered formalin, em-
bedded in parafﬁn, sequential sectioned to 4-μm thickness, and
stained with haematoxylin and eosin (HE) prior to examination
by light microscopy. For immunohistochemistry analysis, staining
methods included antigen retrieval with citrate buffer. A rabbit-
serum-derived polyclonal antibody against nucleoprotein (Sino Biolog-
ical Inc., cat: 100213-RP02) at 1:1000 dilution, was then incubated with
the sections. The secondary antibody used was goat anti-rabbit (ZSGB-
Bio, cat: pv-9001) at 1:2000. Finally, results were evaluated using light
microscopy. To acquire a subject result, different and multiple sites of
the lung, trachea, spleen and kidney tissue samples were collected for
the histopathology and immunohistochemistry analysis. Finally, quanti-
tation of 4–5 slides per animal was used to assess the effect and impact
of the immunized animals.were immunised three times intramuscularly (i.m.), at intervals of 8 or 17 weeks, and in-
ere bled periodically at 2, 10, and 25weeks (−14 days), and at−1 day, 1 day and 3 days.
yswere performed 1 day before inoculation, and at 1 and 3 dpi. Following euthanasia, lung,
tion.
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Statistical analyses were conducted using one-way ANOVA with
Bonferroni post-test via the SPSS for Windows software package (ver.
17, SPSS Inc., Chicago, IL, USA). Unpaired two-tailed Student's t test
was used to compare means between different groups. A value of
p b 0.05 was taken to indicate statistical signiﬁcance. Results are
expressed as mean ± SD. All ﬁgures were rendered using the Prism 5
software package (GraphPad Software, CA, USA).
3. Results
3.1. rRBD Vaccination Induced Sustained and Robust Immunity in the
Rhesus Macaque
To assess the humoral immune response to the rRBD vaccine in
rhesusmacaques, total anti-MERS-CoVRBD IgG antibody titreswere de-
termined by ELISA. Low titres of IgG in serum samples before prime vac-
cination were detected, possibly due to non-speciﬁc responses. IgG
titres in the high-dose group increased signiﬁcantly (p b 0.05) afterFig. 2. Humoral and cellular immune responses induced by rRBD vaccination. a. RBD-speciﬁc
by ELISA. b–d. Neutralisation antibody titres in the sera of immunised rhesus macaques 2 we
(i.e. third) vaccination booster were detected using a pseudovirus neutralisation system. e. Se
caques PBMCs derived at the indicated time points after rRBD immunisation. All of the detectiothe ﬁrst vaccination (Fig. 2a), and achieved the highest titre of RBD-
speciﬁc IgG 2 weeks after the second immunisation. Sera IgG titre in
the low-dose group increased (p b 0.05) only after the second
immunisation, to almost the same level as that of the high-dose group.
RBD-speciﬁc IgG in the sera of immunised rhesus macaques was pre-
served for at least 17 weeks without obvious decline. In addition, IgG
titre increased rapidly after a subsequent boost. Increased IgG titre
was particularly marked in the low-dose group.
Circulating neutralising antibody titres were monitored simulta-
neously in a pseudovirus system.Neutralisation antibodieswere detect-
ed only after the second vaccination. When the pseudovirus inhibition
rate was at 50% (PI50), the neutralisation antibody titres of sera
2 weeks after the second vaccination were 1:800 and 1:1600, in the
low- and high-dose groups, respectively (Fig. 2b). Non-speciﬁc
neutralisation antibody titres in the mock group were at 1:300. Detec-
tion of neutralisation antibodies in rRBD immunisedmonkeys persisted
for at least 17 weeks. Neutralisation antibody titres (PI50) of the sera
were at 1:400 and 1:700 in the low- and high-dose groups, respectively
(Fig. 2c). Encouragingly, following the next boost, immunisation
neutralisation antibody titres (PI50) were as high as 1:800 and 1:1200IgG antibody titres at the indicated time points after vaccine inoculation were monitored
eks after the second vaccination; long-term observation (17-weeks) and the subsequent
ra neutralisation antibodies were detected on Vero cells. f. ELISpot analysis of rhesus ma-
ns were replicated for three times. *p b 0.01 and **p b 0.01.
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vaccination at week 10. At all detection time points, high-dose rRBD in-
duced higher neutralisation antibody titres in the pseudovirus system.
Neutralisation antibody titres in sera following rRBD vaccination
were also detected in Vero cells by the hCoV-EMC strain of MERS-CoV.
Neutralisation antibody titres in the sera of rRBD immunised monkeys
at week 10 were at 1:269 and 1:363 in the low- and high-dose groups,
respectively (Fig. 2e). After 17 weeks, neutralisation antibody titres
decreased slightly. Following a subsequent immunisation boost,
neutralisation antibodies 1 day pre- MERS-CoV challenge were almost
as high as at week 10. At all detection time points, non-speciﬁc
neutralisation antibody titres in the mock group were lower or equal
to 1:10.
To assess the T-cell immune response, rhesus macaque PBMCs de-
rived at different times following rRBD immunisation were stimulated
with overlapping synthetic peptides of RBD; ELISpot analyses were
then conducted. Immunisationwith rRBDproteins induced antigen spe-
ciﬁc IFN-γ-secreting T-cells. In addition, high-dose rRBD induced signif-
icantly higher levels of IFN-γ-secreting T-cells (Fig. 2f).
3.2. rRBD Vaccination Alleviated Pneumonia in the Rhesus Macaque Upon
Challenge With MERS-CoV
Following MERS-CoV challenge, all monkeys were observed twice
daily, with detailed recording of clinical signs, symptoms, morbidity,
and mortality, including the nature, onset, severity, and duration of all
gross or visible changes. After challenge, all monkeys, including rRBD-
immunised animals, drastically decreased theirwater intake. No infected
monkeys exhibited excessive weight loss or died during the experiment.
Tomonitor signs of pneumonia inMERS-CoV challenged animals, X-
ray examination was performed 1 day pre-, 1 and 3 days after MERS-
CoV inoculation. Radiography revealed that all monkeys were negative
for pneumonia before MERS-CoV challenge (−1 day). In mock groupFig. 3. Radiographic alterations and lung pathology. a. X-rays from rhesus macaques imaged p
inﬁltration, indicative of pneumonia, are highlighted (circle). b. Gross pathology of the lungs f
in both high and low dose immunisation groups were small and local, which happened in th
dose groups, respectively.animals, local interstitial inﬂammation was detected at 1 dpi, with
pneumonia diffused to adjacent pulmonary lobes at 3 dpi. Pneumonia
generated in the high-dose groupwas delayed to 3 dpi, with inﬁltration
conﬁned to a single lobe (Fig. 3a). Although pneumonia was detected in
low-dose monkeys at 1 dpi, inﬁltration and interstitial inﬂammation
was less severe compared with the mock group.
The gross pathology of challenged animals was investigated and
necropsies were performed at 3 dpi following euthanasia. The lungs of
mock group animals were congested with palpable nodules (Fig. 3b).
Dark red discolouration and multifocal consolidation was consistent
with the interstitial pneumonia indicated by X-ray examination. In con-
trast, haemorrhage and necrosis shown by black circle in the rRBD-
groups were smaller in both high and low dose immunization (Fig. 3b).
To investigate pneumonia followingMERS-CoV infection, histopath-
ological and immunohistochemical analyses were conducted to eluci-
date the effect of rRBD vaccination. Control monkey lung tissues
exhibitedmoderate lesions (Fig. 4a)with abundant alveolar oedema, ﬁ-
brin formation in the hyaline member and a small-to-moderate degree
of macrophage ﬁbrous inﬁltration (Fig. 4b). In contrast, a mild-to-
moderate-sized lesion was observed in the lung tissue of rRBD-
immunised monkeys (Fig. 4c–f). Inﬁltration of inﬂammatory cells was
also detected in the tracheas ofmock groupmonkeys (Fig. 4g). Although
inﬂammatory cell inﬁltration and impaired epithelium in the tunica
mucosa bronchiorum were also found in the rRBD vaccination group
(Fig. 4h–i), all of the lesion were alleviated compared to the control
group. Glomerular capsule expansion was observed in the kidneys of
all challenge monkeys (data not shown), but this was considered an in-
cidental, clinically non-signiﬁcant ﬁnding. No speciﬁc pathological
changes were observed in the spleens of immunised monkeys (data
not shown). Viral antigen, using a polyclonal antibody against nucleo-
protein, was found by IHC in the lungs (Fig. 5a–c) and tracheas
(Fig. 5d−f) of all monkeys. No speciﬁc antigen was detected in the kid-
neys of challenged monkeys (data not shown).rior to (−1 day) and post-MERS-CoV inoculation (1 day and 3 days). Areas of interstitial
rom necropsied animals at 3 dpi. Haemorrhage and necrosis indicated by the black circle
e mock group were large and disperse. M, H and L represent the mock, high- and low-
Fig. 4. Histopathological changes in the lungs and tracheas of immunised rhesus macaques following MERS-CoV challenge. Three days after MERS-CoV inoculation, all monkeys were
euthanised. Tissues were collected and stained with haematoxylin and eosin (H & E). a–f. Pathological changes in the lungs of immunised monkeys. The black triangle indicates acute
interstitial pneumonia diffused in lung tissue. The unﬁlled arrow indicates the hyaline member resulting from effusion of ﬁbrin. The black arrow indicates the inﬂux of inﬂammatory
cells. g–i. Pathological ﬁndings of tracheas in immunised rhesusmacaques. The black arrowhighlights the inﬁltration of inﬂammatory cells in the tunicamucosa bronchiorum. The unﬁlled
arrow indicates epithelium impairment in tunica mucosa bronchiorum. M, H and L represent the mock, high- and low-dose groups, respectively.
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Challenge
qRT-PCR, using upE gene primers speciﬁc for MERS-CoV, was con-
ducted to determine viral loads in serum, swabs and tissues, including
lung, trachea and kidney. Viral RNA was detected in throat, nasal and
rectal swabs (Fig. 6a) at 1 dpi and 3 dpi. Similarly, viral RNA in lung
and tracheal tissue homogenate were detected at 3 dpi (Fig. 6b). Com-
pared with control monkeys, the rRBD vaccine decreased (p b 0.05)
viral loads in the oronasopharynx swab, lungs and trachea. No viral
RNA was detected in the kidney or serum of challenged monkeys.
Virus titres of various tissues and swabs of immunised animals were
determined by end-point titration in Vero cells. Viral loads in the lungs
and trachea of control monkeys were as high as 50 and 100 TCID50/mL,
respectively (Table 2), but rRBD-immunised monkeys could not isolate
MERS-CoV from the lungs. Although MERS-CoV could be isolated from
two of the six rRBD-immunised monkeys, virus titres were lower vs.
the mock group.4. Discussion
The MERS virus, which emerged in 2012, is now considered a threat
to global public health. Developing an effective vaccine is important to
control MERS-CoV infection. To date, virus-vector vaccines, such
as recombinant modiﬁed vaccinia virus Ankara (MVA), which ex-
presses full-length MERS-CoV spike protein (MVA-MERS-S), andrecombinant adenoviral vectors encoding the full-length MERS-CoV S
protein (Ad5.MERS-S) and the S1 extracellular domain of S protein
(Ad5.MERS-S1), have been developed and tested for their ability to in-
duce virus-neutralising antibodies in mice (Kim et al., 2014; Song
et al., 2013; Volz et al., 2015). Besides, the rRBD subunit vaccine confers
a highly potent neutralising antibody and T-cell immune response in
mice (Zhang et al., 2014). However, few studies have been assessed in
response to MERS-CoV challenge to verify their efﬁcacy, due to a lack
of animal models. For example, mice (Coleman et al., 2014; Scobey
et al., 2013), hamsters (de Wit et al., 2013a,b) and ferrets (Raj et al.,
2014) had not been proved to infectwithMERS-CoV naturally. Recently,
a small animal model of MERS-CoV infection was developed by trans-
ducing mice with an adenovirus vector expressing human DPP4 (Zhao
et al., 2014). However, MERS-CoV infection in this model is highly de-
pendent on the transduction of cells and the level of DPP4 expression
from the adenovirus vector, and therefore does not necessarily reﬂect
the natural disease process (Falzarano et al., 2014). More recently a
transgenic mouse model of MERS-CoV has been published (Agrawal
et al., 2015). However, in this model, all cells of the mouse express
human DPP4. This kind of non-physiological expression patterns result-
ed in extensive brain infection ofMERS-CoV and rapidly succumbs to in-
fection in mice. Moreover, a novel humanized mouse model of MERS-
CoV infection was developed, though the mice were not acquired by
routine technology (Pascal et al., 2015). Encouragingly, rhesusmacaque
models are naturally permissive toMERS-CoV disease, andmore closely
mimic the disease course in human patients (de Wit et al., 2013a,b;
Munster et al., 2013; Yao et al., 2013). Furthermore, the effects of
Fig. 5. IHC staining of immunised rhesusmacaque lung and trachea 3 days afterMERS-CoV infection by a polyclonal antibody against nucleoprotein. a–c. IHC analysis of lung tissue. d–f. IHC
staining of trachea tissue. Black arrows indicate the distribution of viral antigen. M, H and L represent mock, high- and low-dose groups, respectively.
1444 J. Lan et al. / EBioMedicine 2 (2015) 1438–1446interferon-α2b and ribavirin treatment have been evaluated in these
models (Falzarano et al., 2013a,b). Therefore, we herein assessed rRBD
vaccine efﬁcacy in a NHP model.
Similar as the rRBD protein of SARS-CoVwhich induced high titres of
protective anti-RBD antibody responses in NHPs (Wang et al., 2012), the
rRBD vaccination of MERS-CoV induced effective IgG and neutralisation
antibodies in our rhesus macaque model. Besides, the induced IgG and
neutralisation antibodiesmaintained for at least 17weekswithout obvi-
ous attenuation. Following a subsequent boost, antibody titres reached
almost their previous peak level. There was no evident difference for in-
duction of the humoral immunity between high and low dose groups.
However, high-dose vaccination induced a stronger T-cell responseFig. 6.MERS-CoV loads in the swabs and tissues of immunised rhesusmacaques followingMERS
b. The viral loads in lung and trachea tissue 3 days after MERS-CoV infection. All of the detection
respectively. *p b 0.05.than the low-dose vaccination. Following MERS-CoV challenge, rhesus
macaques exhibited a transient lower respiratory tract infection, in ac-
cordance with previous reports (de Wit et al., 2013a,b; Munster et al.,
2013; Yao et al., 2013). Although infection was also detected in rRBD-
immunised animals, clinical signs were alleviated. Pathological changes
in the lungs and tracheas of rRBD-immunised animals indicated re-
duced, but not fully absent lesions. Using qRT-PCR assay, viral loads in
the lungs, trachea and oropharyngeal swabs of the rRBD vaccination
groups were decreased. Furthermore, rRBD-immunised monkeys could
not isolate MERS-CoV from the lungs while viral loads in the lungs and
trachea ofmockmonkeyswere as high as 50 and100 TCID50/mL, respec-
tively. Consistent with the results of immunity elicited by high and low-CoV infection detected by Real-time-PCR. a. Viral loads in swab samples at 1 dpi and 3 dpi.
s were replicated for three times. M, H and L represent mock, high- and low-dose groups,
Table 2
Virus isolation in rhesus macaque tissues inoculated with MERS-CoV at 1 or 3 dpi (logTCID50/mL).
Group Nasal swab Throat swab Anal swab Lung Trachea Kidney Spleen Serum
1 day 3 days 1 day 3 days 1 day 3 days 3 days 3 days 3 days 3 days 3 days
M – – – – – – 1.67 2 – – –
H – – – – – – – b1 – – –
L – – – – – – – 1 – – –
1445J. Lan et al. / EBioMedicine 2 (2015) 1438–1446dose of rRBD vaccine, the protection against MERS-CoV infection in
monkey could be contributed to the humoral immune especially the
neutralising antibodies rather than the cellular mediated immunity.
Although rRBD vaccination alleviated pneumonia and decreased
viral load in the rhesus macaque upon challenge with MERS-CoV in
this study, it did not prevent the infection of MERS-CoV completely.
The data should be interpretedwith some cautions. First, the rhesusma-
caque models to mimic MERS-CoV infection had inevitable limitations.
In both the present and previous reports, MERS-CoV challenge in the
rhesus macaque models resulted in transient infection of the lower re-
spiratory tract (de Wit et al., 2013a,b; Munster et al., 2013; Yao et al.,
2013) and the more severe or even lethal disease course frequently as-
sociated with human cases was not observed herein (van den Brand
et al., 2015). Therefore, the prophylactic effects of the rRBD vaccine
were not fully demonstrated in this model. Second, MERS-CoV chal-
lenge in the trachea bypasses the natural entry sites, such as nasal mu-
cosa and laryngeal areas of the pharynxwhich showas crucial regions of
mucosal immunity (Sato and Kiyono, 2012), while, the bypassedmuco-
sal immunity is the ﬁrst defence against lots of infectious diseases, in-
cluding MERS-CoV (Neutra and K. P., 2006). Third, the challenge dose
of 6.5 × 107 TCID50, was markedly greater than typical MERS-CoV
exposure in humans.More recently, a progressive and lethal pneumonia
was observed in a MERS-CoV challenged common marmoset model
(Falzarano et al., 2014), in which the infected animals developed vire-
mia, and total RNA sequencing demonstrated the induction of immune
and inﬂammatory pathways (Falzarano et al., 2014). Therefore, the
marmoset model corresponds closely to the disease course in humans
and allows for clearer discrimination between successfully treated and
control animals. Therefore, the protective efﬁcacy of this vaccine candi-
date remains to be tested in a more suitable disease model (e.g. com-
mon marmoset) or humans.
To our knowledge, this study represents the ﬁrst evaluation of the
protective efﬁcacy of a candidate subunit antigen against MERS-CoV in
nonhuman primates. We observed sustained and signiﬁcant antibody
neutralisation and T-cell immunity in rhesus macaques in response to
rRBD of MERS-CoV. Besides, the rRBD vaccination alleviated pneumonia
and decreased viral load in the rhesus macaque upon challenge with
MERS-CoV. In summary, our results provide insight into the immunoge-
nicity of an rRBD subunit vaccine against MERS-CoV. All these data indi-
cate that the subunit rRBD vaccine confers partial protection against
MERS-CoV challenge in rhesus macaques, which could be useful for fu-
ture MERS-CoV vaccine trials and prevention strategies.Competing Interests
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